Clinical trials: Rabies Virus Infection
Efficacy of the New CPRV
Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV
Pre exposure rabies vaccination with a new Chromatographically Purified Vero-cell Rabies Vaccine(SPEEDA) is as effective as Purified Vero-cell Rabies vaccine.
- Trial name
- NCT01603875
- Testing
- New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).
- Where
- Thailand
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Malaria, Plasmodium Falciparum Malaria
FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria is a disease that affects many people in Africa and in Mali. It is caused by germs that are spread by mosquito bites. This study will look at the safety, effectiveness, and best dose of an experimental malaria vaccine in…
- Trial name
- NCT00349713
- Testing
- FMP2.1/AS02A, Rabies vaccine (RabAvert)
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Rabies (Healthy Volunteers)
Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.
A multicentre, open label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens (2 x 1IM regimen, 2 x 2 ID regimen, 1 x 2 ID regimen) when administering a single-dose…
- Trial name
- BAZOOKA_221 (NCT07455318)
- Testing
- Booster vaccination
- Where
- 6 sites in Belgium
- Volunteers
- 561 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Healthy Participants
Washington University WU 409: Immune Responses to Rabies Vaccine.
This study will evaluate the immune response to rabies vaccination persons 18 years and older. We will evaluate thirty healthy participants across three cohorts: 1) standard rabies pre-exposure prophylaxis regimen (two doses of…
- Trial name
- NCT07399951
- Testing
- Imovax, RabAvert, HyperRAB
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Rabies Virus Infection
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people
- Trial name
- NCT06548139
- Testing
- Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg, Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg, Rabies Human Immunoglobulin (HRIG)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Rabies
Immunogenicity and Safety of Verorab™ in Indian Population
To demonstrate that rabies vaccine administered according to the Thai Red Cross, (TRC)-ID regimen (2-2-2-0-1-1) is not inferior to rabies vaccine administered according to the ESSEN IM regimen in terms of Geometric Mean Titers…
- Trial name
- NCT00260351
- Testing
- Purified Verocell Rabies Vaccine
- Where
- 3 sites in India
- Volunteers
- 405 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults
A four-site intradermal rabies booster vaccination in HIV - infected patients who have ever received primary rabies vaccination could improve their immune response to this kind of vaccine.
- Trial name
- NCT02547727
- Testing
- rabies vaccine
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Queen Saovabha Memorial Institute
Communicable Disease Transmission, Zoonotic Disease
A Bridging Study of the SYN023 on Healthy Adult Subjects
The Phase I bridging clinical trial is to evaluate on the safety, pharmacokinetics (PK), pharmacodynamics (PD) and ADA of a single intramuscular injection of recombinant anti-rabies human monoclonal antibody injection (SYN023)…
- Conditions
- Communicable Disease Transmission, Zoonotic Disease, Rabies Human, Vaccine Reaction
- Trial name
- NCT04495569
- Testing
- recombinant anti-rabies human monoclonal antibody injection (SYN023), Rabies Vaccine
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Intradermal (ID) Vaccination Device
Intradermal Rabies Immunization Using NanoJect: A Comparative Study
The study is planned as a single-center, randomized, double-blind placebo-controlled, comparative Phase I, first-in-man study to assess the safety and tolerability of the NanoJect™ device, and the immunogenicity of the rabies…
- Trial name
- NCT02538185
- Testing
- NanoJect device (DebioJect™), Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus), Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Lausanne Hospitals
Rabies
Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)
This study was intended to explore the safety and immunogenicity of the test vaccine compared to the control vaccine. The trial consisted of two phases. Phase I used an open-ended design.
- Trial name
- NCT05969626
- Testing
- 5-dose group of test vaccine, 5-dose group of control vaccine, 4-dose A group of test vaccine
- Where
- 4 sites in China
- Volunteers
- 2,460 people, healthy volunteers welcome
- Sponsor
- Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Rabies, Prevention
A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried
This is a phase III, randomized, comparator-controlled, double-blind, multicenter study to evaluate lot-to-lot consistency of three lots of a PIKA Rabies Vaccine, immunogenicity and safety in healthy adults using a post-exposure…
- Trial name
- NCT05667974
- Testing
- PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried, Chirorab
- Where
- 7 sites in Pakistan, Philippines
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
Rabies
Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccine
This is a phase II randomised, open-label study to assess the safety and immunogenicity of coadministration of the candidate rabies vaccine ChAdOx2 RabG and licensed vaccine in healthy adults (18-45 years old).
- Trial name
- NCT07168018
- Testing
- Coadministration of ChAdOx2 RabG and licensed inactivated rabies vaccine (IRV), Inactivated Rabies Vaccine (IRV)
- Where
- Tanzania
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Rabies
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
The aim of the study is to document immunogenicity and safety of VRVg in a pre-exposure regimen in healthy children and adolescents aged 2 to 17 years.
- Trial name
- NCT01930357
- Testing
- Purified Vero Rabies Vaccine Serum Free (VRVg), Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),
- Where
- 2 sites in Philippines
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
This is a Phase Ib/II, open-label, head-to-head, age de-escalation dose-escalation, partially randomized trial to study the safety and immunogenicity of the candidate rabies vaccine ChAdOx2 RabG in healthy adults (age 18-45…
- Trial name
- NCT04270838
- Testing
- ChAdOx2 RabG, Inactivated Rabies Vaccine
- Where
- Tanzania
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Yellow Fever, Rabies
A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of AVX70120 and of AVX70481 in healthy participants.
- Trial name
- SAFYR (NCT06998004)
- Testing
- AVX70120 low dose level, AVX70120 middle dose level, AVX70120 high dose level
- Where
- 2 sites in Belgium
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- AstriVax Therapeutics
Rabies Exposure, Immunocompromised
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients…
- Conditions
- Rabies Exposure, Immunocompromised, Chronic Disease
- Trial name
- NCT07120464
- Testing
- Observation Only
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Rabies (Healthy Volunteers)
Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried
To evaluate the immunogenicity and safety of different post-exposure prophylaxis (PEP) schedules of Sinovac rabies vaccine, in comparison with a marked rabies vaccinein china, in subjects aged 10-60 years old.
- Trial name
- NCT07357545
- Testing
- Sinovac rabies vaccine, Marketed rabies vaccine
- Where
- 2 sites in China
- Volunteers
- 2,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Safety, Immunogenicity
Safety and Immunogenicity of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans
The purpose of this study is to evaluate the safety and immunogenicity of freeze-dried rabies vaccine (MRC-5 cells)in different age health human populations, according to the traditional Essen methods (1-1-1-1-1) vaccination.
- Trial name
- NCT02288286
- Testing
- 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old, 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old, 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
Rabies
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2.
- Trial name
- KAMRAB-003 (NCT02040090)
- Testing
- Active rabies vaccine (US-FDA approved)
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Kamada, Ltd.
Rabies Vaccine Adverse Reaction
Safety of Rabivax-S for Pre-exposure Prophylaxis
People who are at frequent or continuous risk of exposure to rabies virus should be vaccinated against the disease (pre-exposure prophylaxis).
- Trial name
- NCT03741270
- Testing
- Rabivax-S
- Where
- Saint Kitts and Nevis
- Volunteers
- 159 people
- Sponsor
- Ross University School of Veterinary Medicine